Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Anatomic location of measurable uninjected lesions in talimogene laherparepvec study

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

  Any Evaluablea
n (%) n (%)
Any uninjected non-visceral, number of patients (%) 49 (100) 42 (100)
Any non-visceral, number of patients (%) 48 (98.0) 39 (92.9)
 Head/Neck, Front, number of lesions (%) 2 (4.1) 1 (2.4)
 Head/Neck, Back 1 (2.0) 1 (2.4)
 Head/Neck, Right 4 (8.2) 4 (9.5)
 Head/Neck, Left 4 (8.2) 4 (9.5)
 Trunk, Front 13 (26.5) 10 (23.8)
 Trunk, Back 6 (12.2) 5 (11.9)
 Lower Limb, Right 5 (10.2) 5 (11.9)
 Lower Limb, Left 8 (16.3) 8 (19.0)
 Upper Limb, Right 4 (8.2) 3 (7.1)
 Upper Limb, Left 2 (4.1) 1 (2.4)
 Right Hand, Palm 1 (2.0) 1 (2.4)
 Right Hand, Back 1 (2.0) 1 (2.4)
 Groin 2 (4.1) 2 (4.8)
 Lymph node, specify 21 (42.9) 16 (38.1)
 Other 16 (32.7) 8 (19.0)
Any visceral, number of patients (%) 23 (46.9) 15 (35.7)
 Eye, number of lesions (%) 1 (2.0) 0 (0.0)
 Brain 3 (6.1) 0 (0.0)
 Lung 17 (34.7) 12 (28.6)
 Gastrointestinal Tract 3 (6.1) 1 (2.4)
 Kidney 3 (6.1) 0 (0.0)
 Adrenal 4 (8.2) 1 (2.4)
 Liver 8 (16.3) 4 (9.5)
 Pancreas 3 (6.1) 2 (4.8)
 Spleen 4 (8.2) 0 (0.0)
  1. Denominator is the total number of patients. Patients may have multiple lesions
  2. aEvaluable indicates at least 2 assessments with valid measurements
  3. All patients received at least one dose of talimogene laherparepvec